and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed ...
Pre-Market: 9:02:27 a.m. EDT Loading Chart for MIST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback